Loxapine
Links shared publicly online about this topic
Combination Loxapine and Aripiprazole for Refractory Hallucinations in Schizophrenia
theannals.com — “Combination Loxapine and Aripiprazole for Refractory Hallucinations in Schizophrenia” View full resource at theannals.com
Most Recently Shared on July 21, 2011 at 7:15 pm By:
Combination Loxapine and Aripiprazole for Refractory Hallucinations in Schizophrenia: OBJECTIVE: To document the... http://bit.ly/nh9m5v
Alexza Announces Submission Of AZ-004 (Staccato(R) Loxapine) NDA
medicalnewstoday.com — “Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has submitted its New Drug Application (NDA) for Staccato® loxapine (AZ-004) to the US Food and Drug Administration (FDA). AZ-004” View full resource at medicalnewstoday.com
Most Recently Shared on December 16, 2009 at 11:17 am By:
MNT Clinical Trials Health News
Alexza Announces Submission Of AZ-004 (Staccato(R) Loxapine) NDA http://mnt.to/3vxf
Alexza Announces Resubmission of AZ-004 (Staccato Loxapine) NDA
drugs.com — “AZ-004 (Staccato loxapine) is a new drug in development for the treatment of agitation in patients with schizophrenia or bipolar disorder. AZ-004 information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on August 6, 2011 at 1:15 am By:
Drugs and Devices OW OW Health
Alexza Announces Resubmission of AZ-004 (Staccato Loxapine) NDA: MOUNTAIN VIEW, Calif., Aug. 5, 2011 /PRNe... http://bit.ly/oqeC1F #drug
Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato Loxapine) NDA
drugs.com — “AZ-004 (Staccato loxapine) is a new drug in development for the treatment of agitation in patients with schizophrenia or bipolar disorder. AZ-004 information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on October 11, 2010 at 11:11 pm By:
Drugs and Devices OW OW Health
Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato Loxapine) NDA: MOUNTAIN VIEW, C... http://bit.ly/drBmdK #drug
Alexza Announces Adasuve Staccato (Loxapine) PDUFA Goal Date of February 4, 2012
drugs.com — “Adasuve (loxapine) is a new drug in development for the treatment of agitation in adults with schizophrenia or bipolar disorder. Adasuve information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on August 25, 2011 at 1:18 am By:
Drugs and Devices OW OW Health
Alexza Announces Adasuve Staccato (Loxapine) PDUFA Goal Date of February 4, 2012: MOUNTAIN VIEW, Calif., A... http://t.co/aym2Xh8 #drug
News - Inhaled Loxapine Quickly Reduces Agitation in Patients With Schizophrenia, Bipolar Disorder: Presented at EPA
docguide.com — “Inhaled Loxapine Quickly Reduces Agitation in Patients With Schizophrenia, Bipolar Disorder: Present” View full resource at docguide.com
Most Recently Shared on March 5, 2010 at 12:46 am By:
Peter H Brown Doctor and Psychologist
Inhaled Loxapine Quickly Reduces Agitation in Patients With Schizophrenia ... http://bit.ly/90ZOKU #bipolar
Combination Loxapine and Aripiprazole for Refractory Hallucinations in Schizophrenia (July/August) -- Sokolski, 10.1345/aph.1Q088 -- The Annals of Pharmacotherapy
theannals.com — “Combination Loxapine and Aripiprazole for Refractory Hallucinations in Schizophrenia (July/August) -- Sokolski, 10.1345/aph.1Q088 -- The Annals of Pharmacotherapy” View full resource at theannals.com
Most Recently Shared on June 14, 2011 at 10:27 pm By:
Combination Loxapine and Aripiprazole for Refractory Hallucinations in Schizophrenia (July/August): OBJECTIVETo ... http://bit.ly/jtFcUY
Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten... -- NEW ORLEANS, May 26 /PRNewswire-FirstCall/ --
prnewswire.com — “Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder. Additional Phase 3 Analyses and Phase 1 Cardiovascular Safety Data Presented by Alexza Pharmaceuticals at the American Psychiatric Association 2010 Annual Meeting.” View full resource at prnewswire.com
Most Recently Shared on May 27, 2010 at 10:04 am By:
Dr Stephen Ayer - Schizophrenia Society of Nova Scotia Health Organization
Loxapine Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with SZ or BD: http://goo.gl/EKdE
Alexza Announces Adasuve(TM) (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012 - MarketWatch
marketwatch.com — “Alexza Announces Adasuve(TM) (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012 - MarketWatch” View full resource at marketwatch.com
Most Recently Shared on August 19, 2011 at 2:08 pm By:
Peter H Brown Doctor and Psychologist
Alexza Announces Adasuve(TM) (Staccato® Loxapine) PDUFA Goal Date of February ... http://t.co/3ssUlkU #bipolar
Toxicity, Neuroleptic Agents: eMedicine Emergency Medicine
emedicine.medscape.com — “Overview: The neuroleptic agents are antipsychotic drugs that reduce confusion, delusions, hallucinations, and psychomotor agitation in patients with psychoses. The first-generation neuroleptic agents comprise a group of the following 7 classes of drugs: Phenothiazines, further divided into ...” View full resource at emedicine.medscape.com
Most Recently Shared on May 4, 2010 at 1:15 am By:
Overdose of antipsychotic medication is more common among psychiatric patients than other individuals. http://bit.ly/aipfxc
FDA Committee Recommends Approval Of ADASUVE For Bipolar And Schizophrenia
medicalnewstoday.com — “The Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) voted to recommend that ADASUVE(TM) (Staccato® loxapine) be approved for use as a single” View full resource at medicalnewstoday.com
Most Recently Shared on December 13, 2011 at 8:26 pm By:
FDA Committee Recommends Approval Of ADASUVE For Bipolar And Schizophrenia: The Psychopharmacologic Drugs Adviso... http://t.co/vv9Uhz2W
Alexza Pharmaceuticals — Investor Relations - RSS Content
phx.corporate-ir.net — “Alexza Pharmaceuticals Welcome” View full resource at phx.corporate-ir.net
Most Recently Shared on August 5, 2011 at 1:15 pm By:
eyeonfda Health Lawyer and Pharma
Alexza Announces Resubmission of AZ-004 (Staccato® Loxapine) NDA 4 #Schizophrenia or #Bipolar Disorder - http://ow.ly/5VZLR #FDA
Alexza Pharmaceuticals " Investor Relations - RSS Content
phx.corporate-ir.net — “Alexza Pharmaceuticals Welcome” View full resource at phx.corporate-ir.net
Most Recently Shared on October 11, 2010 at 1:25 pm By:
eyeonfda Health Lawyer and Pharma
Alexza Gets Complete Response Letter for AZ-004 (Staccato(R) Loxapine) (for agitation in bipolar/schizophrenia pts) NDA http://ow.ly/2RBNW
NDA Accepted for Adasuve for Agitation in Schizophrenia - MPR
empr.com — “Alexza Pharmaceuticals announced that the FDA has accepted its new drug application (NDA) for Adasuve (Staccato loxapine) for the rapid treatment of agitation in adults with schizophrenia.” View full resource at empr.com
Most Recently Shared on August 19, 2011 at 4:02 pm By:
NDA Accepted for Adasuve for Agitation in Schizophrenia http://ow.ly/67DhH #schizophrenia
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
The Annals
The Annals of Pharmacotherapy is a peer-reviewed medical journal advancing drug therapy by publishing evidence-based pharmacy research and clinical reviews.
-
MNT Clinical Trials
The latest clinical trials news published daily. Articles from research centers, universities and prestigious journals.
-
Drugs and Devices OW
Organizing drug and medical device resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
